Floatz logo

TACROLIMUS

Immune Deficiency Disease

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Immune Deficiency Disease cohort.

Asset / SponsorPhaseRating
Busulphan
University of California, San Francisco
Phase 2BB
Evomela
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB
Thiotepa
University of California, San Francisco
Phase 2BB
HUMAN IMMUNOGLOBULINS
Grifols Therapeutics LLC
Phase 3B

View all 23 →

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →